NR565 Week 4 Midterm Exam Review
Questions And Correct Answers (Verified
Answers) Plus Rationales 2026 Q&A |
Instant Download Pdf
1. A patient with a history of chronic kidney disease stage 4 is prescribed a
medication that is primarily excreted renally. The prescriber adjusts the
dose based on the patient's estimated glomerular filtration rate. This
adjustment is crucial to prevent which of the following adverse outcomes?
A. Exacerbation of the underlying kidney disease
B. Increased risk of hypersensitivity reactions
C. Drug accumulation and subsequent toxicity
D. Reduced therapeutic efficacy of the medication
Answer: C
Rationale: In chronic kidney disease, renal excretion is impaired, leading
to the accumulation of drugs and their active metabolites. Dose
adjustment based on renal function is essential to prevent drug toxicity,
not to exacerbate the kidney disease itself, nor is it primarily related to
hypersensitivity or reduced efficacy in this context.
2. A nurse practitioner is prescribing a drug that is a weak acid. The patient
reports experiencing heartburn and takes an over-the-counter antacid. The
NP should be most concerned about a potential alteration in drug
absorption due to changes in which physiological parameter?
A. Gastric emptying time
B. Intestinal blood flow
C. Gastrointestinal pH
D. Surface area of the small intestine
Answer: C
Rationale: Weak acids are better absorbed in an acidic environment where
, they are non-ionized and more lipophilic. Antacids raise gastric pH,
increasing the ionized fraction of the weak acid and decreasing its
absorption. This is a direct effect of pH on drug ionization, not primarily on
emptying, blood flow, or surface area.
3. A drug has a volume of distribution of 40 L. This value indicates that the
drug is:
A. Primarily confined to the plasma compartment
B. Evenly distributed throughout total body water
C. Concentrated in extracellular fluid
D. Highly distributed into tissue compartments
Answer: D
Rationale: A Vd of 40 L is greater than total body water (approx. 42 L) and
significantly larger than plasma volume (3 L) or extracellular fluid (14 L). A
large Vd suggests the drug has extensively distributed into tissues, leaving
a lower concentration in the plasma.
4. A patient is started on a new medication and achieves steady-state plasma
concentrations after approximately four half-lives. This principle is
important for the NP to understand because it determines:
A. The time required to reach the minimum effective concentration
B. The duration of time the drug remains in the body after discontinuation
C. The time to achieve a plateau in plasma drug levels with repeated dosing
D. The peak plasma concentration after a single dose
Answer: C
Rationale: Steady-state is the point at which the rate of drug
administration equals the rate of drug elimination, resulting in a plateau
in plasma concentrations. This is achieved after approximately 4-5 half-
lives, regardless of the dosing interval. The other options describe
different pharmacokinetic parameters.
5. A drug with a narrow therapeutic index requires therapeutic drug
monitoring. Which of the following factors would most likely necessitate a
more frequent monitoring schedule for this drug?
, A. The patient is a young adult with no other medical conditions
B. The drug is administered via the oral route
C. The patient has a stable, consistent dietary intake
D. The patient is concurrently taking an enzyme-inducing medication
Answer: D
Rationale: Enzyme-inducing medications can alter the metabolism of
drugs with a narrow therapeutic index, causing subtherapeutic or
supratherapeutic levels. This unpredictable change in drug clearance
necessitates closer monitoring to maintain efficacy and avoid toxicity. The
other options are associated with more predictable pharmacokinetics.
6. An NP is considering prescribing a drug that has a high first-pass effect. To
ensure maximum systemic bioavailability, the NP should consider which
route of administration?
A. Oral
B. Subcutaneous
C. Intramuscular
D. Sublingual
Answer: D
Rationale: The first-pass effect occurs when a drug is metabolized in the
liver before reaching systemic circulation. Sublingual administration
allows the drug to be absorbed directly into the systemic circulation via
the venous system, bypassing the hepatic portal circulation and thus
avoiding the first-pass effect. Oral, subcutaneous, and intramuscular
routes do not reliably bypass this effect.
7. A patient’s renal function is declining, as evidenced by a decreasing
creatinine clearance. The NP is managing a medication that is 70% renally
excreted. The most appropriate initial action to prevent adverse effects is
to:
A. Increase the dose to maintain therapeutic effect
B. Switch to a medication that is hepatically metabolized
C. Decrease the dose or increase the dosing interval
D. Discontinue the drug and monitor for symptoms
, Answer: C
Rationale: In renal impairment, the clearance of renally excreted drugs is
reduced, leading to accumulation. The primary strategy to prevent toxicity
is to reduce the dose or prolong the dosing interval to achieve a similar
area under the curve (AUC) as in patients with normal renal function.
Increasing the dose would worsen toxicity.
8. Which of the following pharmacokinetic processes is primarily responsible
for the termination of drug action?
A. Absorption
B. Distribution
C. Metabolism and Excretion
D. Protein Binding
Answer: C
Rationale: Drug action is terminated when the drug is removed from its
site of action. This is accomplished through metabolism
(biotransformation into inactive metabolites) and excretion (elimination
from the body). While distribution can move a drug away from its site of
action, it does not eliminate it from the body.
9. A patient is receiving a drug that is highly protein-bound. The NP
understands that if a second highly protein-bound drug is administered
concurrently, the most likely result is:
A. A decreased concentration of the free (active) form of the first drug
B. A significant increase in the volume of distribution of the first drug
C. A temporary increase in the free (active) fraction of the first drug
D. An immediate reduction in the renal clearance of the first drug
Answer: C
Rationale: Displacement interactions occur when a second drug competes
for the same protein-binding sites. This causes a transient increase in the
free (unbound) concentration of the first drug, potentially leading to
increased pharmacologic effect or toxicity. The free fraction is increased,
not decreased.
Questions And Correct Answers (Verified
Answers) Plus Rationales 2026 Q&A |
Instant Download Pdf
1. A patient with a history of chronic kidney disease stage 4 is prescribed a
medication that is primarily excreted renally. The prescriber adjusts the
dose based on the patient's estimated glomerular filtration rate. This
adjustment is crucial to prevent which of the following adverse outcomes?
A. Exacerbation of the underlying kidney disease
B. Increased risk of hypersensitivity reactions
C. Drug accumulation and subsequent toxicity
D. Reduced therapeutic efficacy of the medication
Answer: C
Rationale: In chronic kidney disease, renal excretion is impaired, leading
to the accumulation of drugs and their active metabolites. Dose
adjustment based on renal function is essential to prevent drug toxicity,
not to exacerbate the kidney disease itself, nor is it primarily related to
hypersensitivity or reduced efficacy in this context.
2. A nurse practitioner is prescribing a drug that is a weak acid. The patient
reports experiencing heartburn and takes an over-the-counter antacid. The
NP should be most concerned about a potential alteration in drug
absorption due to changes in which physiological parameter?
A. Gastric emptying time
B. Intestinal blood flow
C. Gastrointestinal pH
D. Surface area of the small intestine
Answer: C
Rationale: Weak acids are better absorbed in an acidic environment where
, they are non-ionized and more lipophilic. Antacids raise gastric pH,
increasing the ionized fraction of the weak acid and decreasing its
absorption. This is a direct effect of pH on drug ionization, not primarily on
emptying, blood flow, or surface area.
3. A drug has a volume of distribution of 40 L. This value indicates that the
drug is:
A. Primarily confined to the plasma compartment
B. Evenly distributed throughout total body water
C. Concentrated in extracellular fluid
D. Highly distributed into tissue compartments
Answer: D
Rationale: A Vd of 40 L is greater than total body water (approx. 42 L) and
significantly larger than plasma volume (3 L) or extracellular fluid (14 L). A
large Vd suggests the drug has extensively distributed into tissues, leaving
a lower concentration in the plasma.
4. A patient is started on a new medication and achieves steady-state plasma
concentrations after approximately four half-lives. This principle is
important for the NP to understand because it determines:
A. The time required to reach the minimum effective concentration
B. The duration of time the drug remains in the body after discontinuation
C. The time to achieve a plateau in plasma drug levels with repeated dosing
D. The peak plasma concentration after a single dose
Answer: C
Rationale: Steady-state is the point at which the rate of drug
administration equals the rate of drug elimination, resulting in a plateau
in plasma concentrations. This is achieved after approximately 4-5 half-
lives, regardless of the dosing interval. The other options describe
different pharmacokinetic parameters.
5. A drug with a narrow therapeutic index requires therapeutic drug
monitoring. Which of the following factors would most likely necessitate a
more frequent monitoring schedule for this drug?
, A. The patient is a young adult with no other medical conditions
B. The drug is administered via the oral route
C. The patient has a stable, consistent dietary intake
D. The patient is concurrently taking an enzyme-inducing medication
Answer: D
Rationale: Enzyme-inducing medications can alter the metabolism of
drugs with a narrow therapeutic index, causing subtherapeutic or
supratherapeutic levels. This unpredictable change in drug clearance
necessitates closer monitoring to maintain efficacy and avoid toxicity. The
other options are associated with more predictable pharmacokinetics.
6. An NP is considering prescribing a drug that has a high first-pass effect. To
ensure maximum systemic bioavailability, the NP should consider which
route of administration?
A. Oral
B. Subcutaneous
C. Intramuscular
D. Sublingual
Answer: D
Rationale: The first-pass effect occurs when a drug is metabolized in the
liver before reaching systemic circulation. Sublingual administration
allows the drug to be absorbed directly into the systemic circulation via
the venous system, bypassing the hepatic portal circulation and thus
avoiding the first-pass effect. Oral, subcutaneous, and intramuscular
routes do not reliably bypass this effect.
7. A patient’s renal function is declining, as evidenced by a decreasing
creatinine clearance. The NP is managing a medication that is 70% renally
excreted. The most appropriate initial action to prevent adverse effects is
to:
A. Increase the dose to maintain therapeutic effect
B. Switch to a medication that is hepatically metabolized
C. Decrease the dose or increase the dosing interval
D. Discontinue the drug and monitor for symptoms
, Answer: C
Rationale: In renal impairment, the clearance of renally excreted drugs is
reduced, leading to accumulation. The primary strategy to prevent toxicity
is to reduce the dose or prolong the dosing interval to achieve a similar
area under the curve (AUC) as in patients with normal renal function.
Increasing the dose would worsen toxicity.
8. Which of the following pharmacokinetic processes is primarily responsible
for the termination of drug action?
A. Absorption
B. Distribution
C. Metabolism and Excretion
D. Protein Binding
Answer: C
Rationale: Drug action is terminated when the drug is removed from its
site of action. This is accomplished through metabolism
(biotransformation into inactive metabolites) and excretion (elimination
from the body). While distribution can move a drug away from its site of
action, it does not eliminate it from the body.
9. A patient is receiving a drug that is highly protein-bound. The NP
understands that if a second highly protein-bound drug is administered
concurrently, the most likely result is:
A. A decreased concentration of the free (active) form of the first drug
B. A significant increase in the volume of distribution of the first drug
C. A temporary increase in the free (active) fraction of the first drug
D. An immediate reduction in the renal clearance of the first drug
Answer: C
Rationale: Displacement interactions occur when a second drug competes
for the same protein-binding sites. This causes a transient increase in the
free (unbound) concentration of the first drug, potentially leading to
increased pharmacologic effect or toxicity. The free fraction is increased,
not decreased.
